This case-based educational activity is designed to update urologists on emerging treatment options for patients with superficial bladder cancer.

After participating in this activity, physicians will be better able to:

• Describe the clinical characteristics, staging, and grading of bladder cancer as they relate to clinical decision making
  
  
• Discuss the strengths and weaknesses of current treatments for both disease eradication and prevention of recurrence
  
  
• Describe the benefits of rIFN-a2b as second-line monotherapy or in combination with BCG, as illustrated in selected case studies
  
  
• Apply the lessons learned from the case studies about the use of rIFN-a2b to improve the clinical outcomes of patients with superficial bladder cancer